Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TDQ0
UPID:
HAVR2_HUMAN
Alternative names:
T-cell immunoglobulin and mucin domain-containing protein 3; T-cell immunoglobulin mucin receptor 3; T-cell membrane protein 3
Alternative UPACC:
Q8TDQ0; B2RAY2; Q8WW60; Q96K94
Background:
Hepatitis A virus cellular receptor 2, also known as T-cell immunoglobulin and mucin domain-containing protein 3, plays a crucial role in modulating immune responses. It functions as a cell surface receptor that can either inhibit or stimulate T-cell responses depending on the cellular context and the ligand involved. Its ability to regulate macrophage activation and promote immunological tolerance highlights its significance in immune regulation.
Therapeutic significance:
The protein's involvement in T-cell lymphoma, subcutaneous panniculitis-like, underscores its therapeutic potential. Understanding the role of Hepatitis A virus cellular receptor 2 could open doors to potential therapeutic strategies for treating this uncommon form of T-cell non-Hodgkin lymphoma and possibly other autoimmune disorders.